Comparison of BRCA versus non-BRCA germline mutations and associated somatic mutation profiles in patients with unselected breast cancer.
The data on the phenotypes associated with some rare germline mutations in Chinese breast cancer patients are limited. The difference in somatic mutation profiles in breast cancer patients with germline BRCA and non-BRCA mutations remains unexplored. We interrogated the germline and somatic mutational profile of 524 Chinese breast cancer patients with various stages unselected for predisposing factors using a panel consisting of 520 cancer-related genes including 62 cancer susceptibility genes. We divided the patients into three groups according to germline mutations: Germline-BRCA1/2, Germline-others (non-BRCA) and Others (non-carriers). A total of 58 patients (11.1%) carried 76 likely pathogenic or pathogenic (LP/P) germline variants in 15 cancer predisposition genes. Germline BRCA1/2 mutations were detected from 29 (5.53%) patients; with 11 (2.10%) BRCA1 carriers and 18 (3.44%) BRCA2 carriers. In addition, LP/P germline mutations were detected in other genes including MUTYH (n=4), PALB2 (n=4), ATM (n=3), BRIP1 (n=3), CDH1 (n=3), RAD51C (n=3), CHEK2 (n=2), FANCA (n=2), PMS2 (n=2), TP53 (n=2), FANCI (n=1), FANCL (n=1) and PTEN (n=1). At least one variant of uncertain significance (VUS) was identified in 490 (93.5%) patients. Young age (P=0.011), premenopausal status (P=0.013), and breast/ovarian cancer family history (P=0.001) were correlated with germline mutations. Germline-BRCA1/2 group was detected with more missense (P=0.02) and less copy-number amplification (P=0.04) than Germline-others group. Meanwhile, Germline-others group and Others group are very similar (P>0.05). The mutation rates of AKT1, CCND1, FGFR1, and PIK3CA were different among the three groups. By investigating all breast and ovarian cancer-related genes listed in the US genetic guidelines, we identified 15 cancer susceptibility genes frequently mutated in the germline of our population and must be included in cancer predisposition screening. Our study contributed a better understanding of the tumor characteristics of patients with LP/P germline mutations.
['Chen|Bo|B|', 'Zhang|Guochun|G|', 'Li|Xuerui|X|', 'Ren|Chongyang|C|', 'Wang|Yulei|Y|', 'Li|Kai|K|', 'Mok|Hsiaopei|H|', 'Cao|Li|L|', 'Wen|Lingzhu|L|', 'Jia|Minghan|M|', 'Li|Cheukfai|C|', 'Guo|Liping|L|', 'Wei|Guangnan|G|', 'Lin|Jiali|J|', 'Li|Yingzi|Y|', 'Zhang|Yuchen|Y|', 'Han-Zhang|Han|H|', 'Liu|Jing|J|', 'Lizaso|Analyn|A|', 'Liao|Ning|N|']
D000328:Adult D019313:BRCA1 Protein D024682:BRCA2 Protein D001943:Breast Neoplasms D064447:Checkpoint Kinase 2 D004252:DNA Mutational Analysis D000076164:Fanconi Anemia Complementation Group N Protein D005260:Female D020022:Genetic Predisposition to Disease D018095:Germ-Line Mutation D006801:Humans D008875:Middle Aged D051059:PTEN Phosphohydrolase
BRCA non-BRCA germline mutations somatic mutations breast cancer